Literature DB >> 31042327

Study on the relationship between telomere length changes and recurrence of atrial fibrillation after radiofrequency catheter ablation.

Changyang Su1,2,3, Zheng Liu1,2, Yuanfeng Gao1,2, Ye Liu1,2, Rou-Mu Hu1,2, Jia Liu1,2, Xiyan Yang1,2, Shichao Li1,2, Yuan Zhang1,2, Kun Zuo1,2, Boli Cao1,2, Jing Luo1,3, Jing Li1,2, Kuibao Li1,2, Xiandong Yin1,2, Mulei Chen1,2, Xinchun Yang1,2.   

Abstract

INTRODUCTION: Advanced age is the foremost risk factor for atrial fibrillation (AF). Telomere length is a surrogate for biological aging, but the association between shortened leukocyte telomere length (LTL) and recurrence of AF (RAF) after ablation remains inconclusive.
METHODS: In this prospective analysis, 282 patients underwent an initial catheter ablation for paroxysmal or persistent AF. The association between RAF and LTL was analyzed by univariate and multivariate Cox regression, as well as time-dependent receiver operating characteristic (ROC) analysis and Kaplan-Meier analysis.
RESULTS: After a mean follow-up of 14.20 ± 5.04 months, RAF was documented in 78 of the 277 patients who completed the study (28.16%). In Cox proportional hazards models, LTL, age, diagnosis to ablation time (DTAT), N-terminal pronatriuretic peptide, and CHA2DS2-VASc score were significantly associated with RAF. After multivariable adjustment, LTL and DTAT were predicted as independent risk factors for RAF with hazard ratio (HR) of 3.17 (95% confidence interval [CI]: 1.23-8.15, P = 0.017) and 1.43 (95% CI: 1.10-1.86, P = 0.007), respectively. In addition, ROC analysis indicated the potential diagnostic value of LTL with an area under the curve of 0.64 (P < 0.001; sensitivity = 60.3%, specificity = 57.8%), and an optimum cut-off value of 1.040. LTL less than or equal to 1.040 was defined as shortened LTL, while LTL greater than 1.040 nonshortened LTL. Kaplan-Meier analysis showed RAF rate curve was separated significantly between two groups (21.2% vs 35.9%, log-rank test result P = 0.007). Patients with shortened LTL might have a higher risk for RAF with HR = 1.84 (P = 0.008).
CONCLUSIONS: Shortened LTL is an independent risk factor for AF recurrence. Shortened LTL could be a potential biomarker in predicting RAF after ablation.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; atrial fibrillation recurrence; biomarker; risk factors; telomere

Year:  2019        PMID: 31042327     DOI: 10.1111/jce.13958

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Mitochondrial Dysfunction Contributes to Aging-Related Atrial Fibrillation.

Authors:  Chuanbin Liu; Jing Bai; Qing Dan; Xue Yang; Kun Lin; Zihao Fu; Xu Lu; Xiaoye Xie; Jianwei Liu; Li Fan; Yang Li
Journal:  Oxid Med Cell Longev       Date:  2021-04-28       Impact factor: 6.543

2.  Longer diagnosis-to-ablation time is associated with recurrence of atrial fibrillation after catheter ablation-Systematic review and meta-analysis.

Authors:  Raymond Pranata; Veresa Chintya; Sunu B Raharjo; Muhammad Yamin; Yoga Yuniadi
Journal:  J Arrhythm       Date:  2019-12-27

3.  Leukocyte Telomere Length Predicts Progression From Paroxysmal to Persistent Atrial Fibrillation in the Long Term After Catheter Ablation.

Authors:  Qianhui Wang; Zheng Liu; Ying Dong; Xinchun Yang; Mulei Chen; Yuanfeng Gao
Journal:  Front Cardiovasc Med       Date:  2022-01-24

4.  Circulating plasma galectin-3 predicts new-onset atrial fibrillation in patients after acute myocardial infarction during hospitalization.

Authors:  Qianhui Wang; Wei Huai; Xiaoguang Ye; Yuxia Pan; Xinchun Yang; Mulei Chen; Qing-Bian Ma; Yuanfeng Gao; Yuan Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-09-03       Impact factor: 2.174

5.  Shortened leukocyte telomere length as a potential biomarker for predicting the progression of atrial fibrillation from paroxysm to persistence in the short-term.

Authors:  Siyu Wang; Yuanfeng Gao; Lei Zhao; Roumu Hu; Xinchun Yang; Ye Liu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.